Timothy R. Blake

Timothy R. Blake

Auto-generated profile, based on publicly available information

Timothy R. Blake

Department of Chemistry, Stanford University, Stanford, California 94305, United States

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2021 in ACS Central Science
Verified
Journal Article
Open access
OHOle A. W. Haabeth
Ole A. W. Haabeth
JLJulian J. K. Lohmeyer
Julian J. K. Lohmeyer
ASAdrienne Sallets
Adrienne Sallets
TBTimothy R. Blake
Timothy R. Blake
ISIdit Sagiv-Barfi
Idit Sagiv-Barfi
RLRonald Levy
Ronald Levy
The SARS-CoV-2 pandemic has necessitated the rapid development of prophylactic vaccines. Two mRNA vaccines have been approved for emergency use by the FDA and have demonstrated extraordinary effectiveness. The success of these mRNA vaccines establishes the speed of development and therapeutic potential of mRNA. These authorized vaccines encode full-length versions of the SARS-CoV-2 spike protein. They are formulated with lipid nanoparticle (LNP) delivery vehicles that have inherent immunostimulatory properties. Different vaccination strategies and alternative mRNA delivery vehicles would be desirable to ensure flexibility of future generations of SARS-CoV-2 vaccines and the development of mRNA vaccines in general. Here, we report on the development of an alternative mRNA vaccine approach using a delivery vehicle called charge-altering releasable transporters (CARTs). Using these inherently nonimmunogenic vehicles, we can tailor the vaccine immunogenicity by inclusion of coformulated adjuvants such as oligodeoxynucleotides with CpG motifs (CpG-ODN). Mice vaccinated with the mRNA-CART vaccine developed therapeutically relevant levels of receptor binding domain (RBD)-specific neutralizing antibodies in both the circulation and in the lung bronchial fluids. In addition, vaccination elicited strong and long-lasting RBD-specific TH1 T cell responses including CD4+ and CD8+ T cell memory.

20 February 2020 in Chemical Science
Verified
Journal Article
Open access
PDF file
TBTimothy R. Blake
Timothy R. Blake
WHWilson C. Ho
Wilson C. Ho
CTChristopher R. Turlington
Christopher R. Turlington
XZXiaoyu Zang
Xiaoyu Zang
MHMelanie A. Huttner
Melanie A. Huttner
RWRobert M. Waymouth
Robert M. Waymouth
The synthesis and degradation mechanisms of a class of pH-sensitive, rapidly degrading cationic poly(α-aminoester)s are described. These reactive, cationic polymers are stable at low pH in water, but undergo a fast and selective degradation at higher pH to liberate neutral diketopiperazines. Related materials incorporating oligo(α-amino ester)s have been shown to be effective gene delivery agents, as the charge-altering degradative behavior facilitates the delivery and release of mRNA and other nucleic acids in vitro and in vivo. Herein, we report detailed studies of the structural and environmental factors that lead to these rapid and selective degradation processes in aqueous buffers. At neutral pH, poly(α-aminoester)s derived from N-hydroxyethylglycine degrade selectively by a mechanism involving sequential 1,5- and 1,6-O→N acyl shifts to generate bis(N-hydroxyethyl) diketopiperazine. A family of structurally related cationic poly(aminoester)s was generated to study the structural influences on the degradation mechanism, product distribution, and pH dependence of the rate of degradation. The kinetics and mechanism of the pH-induced degradations were investigated by 1H NMR, model reactions, and kinetic simulations. These results indicate that polyesters bearing α-ammonium groups and appropriately positioned N-hydroxyethyl substituents are readily cleaved (by intramolecular attack) or hydrolyzed, representing dynamic “dual function” materials that are initially polycationic and transform with changing environment to neutral products.

30 March 2023 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
TBTimothy R. Blake
Timothy R. Blake
OHOle A. W. Haabeth
Ole A. W. Haabeth
ASAdrienne Sallets
Adrienne Sallets
RMRebecca L. McClellan
Rebecca L. McClellan
TCTrevor J. Del Castillo
Trevor J. Del Castillo
RWRobert M. Waymouth
Robert M. Waymouth

14 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
OHOle A.W. Haabeth
Ole A.W. Haabeth
JLJulian J.K. Lohmeyer
Julian J.K. Lohmeyer
ASAdrienne Sallets
Adrienne Sallets
TBTimothy R. Blake
Timothy R. Blake
ISIdit Sagiv-Barfi
Idit Sagiv-Barfi
RLRonald Levy
Ronald Levy
The SARS-CoV-2 pandemic has necessitated the rapid development of prophylactic vaccines. Two mRNA vaccines have been approved for emergency use by the FDA and have demonstrated extraordinary effectiveness. The success of these mRNA vaccines establishes the speed of development and therapeutic potential of mRNA. These authorized vaccines encode full-length versions of the SARS-CoV-2 spike protein. They are formulated with Lipid Nanoparticle (LNP) delivery vehicles that have inherent immunostimulatory properties. Different vaccination strategies and alternative mRNA delivery vehicles would be desirable to ensure flexibility of future generations of SARS-CoV-2 vaccines and the development of mRNA vaccines in general. Here, we report on the development of an alternative mRNA vaccine approach using a delivery vehicle called Charge-Altering Releasable Transporters (CARTs). Using these inherently nonimmunogenic vehicles we can tailor the vaccine immunogenicity by inclusion of co-formulated adjuvants such as oligodeoxynucleotides with CpG motifs (CpG-ODN). Mice vaccinated with the mRNA-CART vaccine developed therapeutically relevant levels of RBD-specific neutralizing antibodies in both the circulation and in the lung bronchial fluids. In addition, vaccination elicited strong and long lasting RBD-specific T H 1 T cell responses including CD4 + and CD8 + T cell memory.